Consumer protection
Compounded GLP-1 status: what changed and what to verify before paying
A consumer-protection explainer on the public FDA and CMS facts around compounded GLP-1 status, shortage timelines, warning letters, and verification steps.
The short version
Compounded GLP-1 offerings became more complicated after FDA shortage decisions and enforcement timelines changed. This page does not say a product is safe, unsafe, appropriate, or inappropriate for you. It gives dated public facts and the questions to ask before paying a seller.
The practical shopper problem is category confusion. A checkout page may use familiar medicine names, monthly-price language, and fast-start messaging, but the product category, prescriber license, pharmacy identity, and legal basis can differ. Before paying, ask the seller to identify each of those pieces in writing and keep a dated copy.
| Public fact | What it means for shoppers | Verified | Official page |
|---|---|---|---|
| Tirzepatide shortage resolution | FDA shortage status changes can affect whether compounders can rely on shortage-based supply arguments. Ask the seller what legal basis applies now. | 2026-07-08 | FDA GLP-1 compounding policies |
| Semaglutide shortage resolution | Federal shortage updates changed the background for compounded semaglutide marketing. Ask whether the seller is using an FDA-approved product, a compounded preparation, or another category. | 2026-07-08 | FDA GLP-1 compounding policies |
| 503A and 503B timing | FDA described different policy timing for state-licensed pharmacies and outsourcing facilities. The type of facility matters, so ask who prepares the medicine. | 2026-07-08 | FDA GLP-1 compounding policies |
| Warning-letter environment | FDA has sent warning letters involving some GLP-1 marketing. Shoppers should be cautious with seller claims that promise easy access, certain results, or official equivalence. | 2026-07-08 | FDA warning letters |
| Medicare bridge context | CMS describes a federal access path for eligible Medicare beneficiaries with a $50 monthly copay for certain GLP-1 medications. Check eligibility directly with CMS and the plan. | 2026-07-08 | CMS Medicare GLP-1 Bridge |
| License verification | Confirm the prescriber is licensed where you live and that the pharmacy or facility is identified. If the seller will not name the pharmacy path, pause before paying. | 2026-07-08 | State medical board directory |
Questions to ask a seller
Ask whether the product is FDA-approved or compounded, who prescribes it, which pharmacy or facility prepares it, whether the prescriber is licensed in your state, what the total monthly cost is, and how cancellation works. Ask what changes if the product is unavailable or if your insurance denies coverage. Keep written answers before payment.
If a seller answers with broad comfort language instead of names, dates, terms, and official references, slow down. A trustworthy seller should be able to name the prescriber path, the pharmacy path, the renewal amount, the refund rule, and the way to verify professional licensing. That information does not decide your medical care; it helps you avoid confusing or poorly disclosed purchases.
Related reading: Foundayo cost page and oral GLP-1 provider channels.
Questions shoppers ask
- Is compounded the same as FDA-approved?
- No. Ask the seller exactly what category the product is in and who prepares it.
- Should I rely on social ads for pricing?
- No. Use official terms and written checkout terms. Prices and supply routes can change.
- What should I verify first?
- Verify prescriber license, pharmacy or facility identity, total monthly cost, cancellation terms, and whether the product is FDA-approved or compounded.